Information Provided By: 
Fly News Breaks for December 2, 2019
TXMD
Dec 2, 2019 | 07:21 EDT
Guggenheim analyst Dana Flanders initiated coverage of TherapeuticsMD with a Buy rating and $5.00 price target. With three commercial products addressing areas of unmet need, TherapeuticsMD is building a leadership position in Women's Health, said Flanders, who added that he thinks each product offers a distinct advantage over existing therapies. He also believes the company should see a "meaningful improvement" in revenue performance in 2020, though Flanders added that he "won't call 2020 an inflection year."
News For TXMD From the Last 2 Days
There are no results for your query TXMD
